Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether a novel subset of neutrophils is correlated with corneal neovascularization in the patients suffered from ocular chemical injury.


Clinical Trial Description

Cornea is an avascular transparent tissue providing refractive power for suitable optical performance. But under the condition of injury or infection, the stable microenvironment of ocular surface has been destroyed. Vessels sprout from the limbus to form corneal neovascularization, becoming an important pathological feature and leading cause of blindness. However, the underlying mechanism particular the inflammation-mediated mechanism remains unclear. With the advancement of single-cell RNA sequencing (scRNA-seq), the investigation of immune cell transcriptomes has obtained great process . Using this advanced method, we identified different immune cell types in the ocular surface microenvironment in corneal neovascularization mouse model. Particularly, we found a specific subset of neutrophils played important role during the corneal angiogenesis. Using the loss-of-function and gain-of-function experiment, we clarified that this novel subset of neutrophils is the major factor that promoting corneal angiogenesis in mouse model. To further explore the relationship between this subset of neutrophils and angiogenesis in human, we plan to detect whether the neutrophil subset is increased in the circulation of chemical burned corneal neovascularization patients. The main purpose of this study is to assess whether the novel subset of neutrophils has correlation with chemical burned corneal neovascularization. Approximately 33 patients and 33 age matched healthy controls will be recruited. The clinical characteristics, 4ml peripheral blood and the images of slit lamp photography will be obtained. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05659940
Study type Observational
Source Zhongshan Ophthalmic Center, Sun Yat-sen University
Contact Ziqi Yang
Phone 8618826227484
Email yangzq6@mail2.sysu.edu.cn
Status Recruiting
Phase
Start date January 1, 2023
Completion date November 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT00555594 - Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization Phase 2/Phase 3
Completed NCT00004430 - Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization N/A
Completed NCT00769145 - Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery Phase 1
Completed NCT01257750 - Treatment of Corneal Neovascularization With Topical Pazopanib Phase 1/Phase 2
Recruiting NCT04787471 - Corneal Crosslinking for Treatment of Corneal Neovascularization Phase 2/Phase 3
Not yet recruiting NCT06412718 - Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
Active, not recruiting NCT00992849 - Bevacizumab for the Treatment of Corneal Neovascularization Phase 2
Withdrawn NCT00515684 - Corneal Thinning During Topical Bevacizumab Therapy N/A
Terminated NCT02797704 - Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization Phase 1/Phase 2
Terminated NCT01868360 - Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea Phase 1
Withdrawn NCT02042027 - Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions Phase 1
Recruiting NCT04215393 - An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization Phase 1
Completed NCT00797303 - The Effect of Bevacizumab on Corneal Neovascularization Phase 4
Completed NCT00559936 - Topical Avastin for Treatment of Corneal Neovascularization Phase 1
Completed NCT01072357 - Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival Phase 1/Phase 2
Recruiting NCT04620109 - Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment Phase 1
Completed NCT00512876 - Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization N/A
Recruiting NCT05011916 - The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization Phase 1/Phase 2
Completed NCT01996826 - A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival Phase 1/Phase 2
Terminated NCT00915590 - Topical IL-1-Ra for Treatment of Corneal Neovascularization Phase 1/Phase 2